| Literature DB >> 24215052 |
M Keklik1, S Sivgin, O Kontas, U Abdulrezzak, L Kaynar, M Cetin.
Abstract
Langerhans cell sarcoma, a tumour with markedly malignant cytological features that originates from Langerhans cells, is a very rare disease. We report the first case of 39-year-old male with Langerhans cell sarcoma arising in the nasopharynx. We chose the 2-chlorodeoxyadenosine (2-CDA) regimen as first-line chemotherapy, and clinical improvement of Langerhans cell sarcoma was obtained. After the fourth cycle of 2-CDA therapy, however, disease progression was observed, and we administered ESHAP regimen (etoposide, carboplatin, cytarabine, methylprednisolone) as a second-line therapy. After we administered two cycles of ESHAP, however, the patient developed aggressive progression and he died. The importance of immunohistochemical findings is obvious in Langerhans cell sarcoma diagnosis. Considering that Langerhans cell sarcoma behaves in a very malignant fashion, a more aggressive treatment approach is necessary for patients with Langerhans cell sarcoma.Entities:
Keywords: 2-CDA; ESHAP; Langerhans cell sarcoma; nasopharynx
Mesh:
Substances:
Year: 2013 PMID: 24215052 DOI: 10.1177/0036933013508046
Source DB: PubMed Journal: Scott Med J ISSN: 0036-9330 Impact factor: 0.729